**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO: 28378**

**Manuscript Type: Original Article**

***Retrospective Study***

**Recurrence of choledocholithiasis following endoscopic bile duct clearance: long term results and factors associated with recurrent bile duct stones**

Konstantaki*s* C *et al.* Recurrence of choledocholithiasis,rate and clinical - associated factors

**Christos Konstantakis, Christos Triantos, Vasileios Theopistos, Georgios Theocharis, Ioannis Maroulis, Georgia Diamantopoulou, Konstantinos Thomopoulos**

**Christos Konstantakis, Christos Triantos, Vasileios Theopistos, Georgios Theocharis, Ioannis Maroulis, Georgia Diamantopoulou, Konstantinos Thomopoulos,** Department of Gastroenterology, University hospital of Patras, Patras 26504, Greece

**Christos Konstantakis,** Department of Gastroenterology, General hospital of Patras, Patras 26335, Greece

**Author contributions:** Konstantakis C and Thomopoulos K contributed equally to this work; Konstantakis C collected and analyzed the data, and drafted the manuscript; Thomopoulos K provided analytical oversight; Thomopoulos K designed and supervised the study; Triantos C, Theopistos V, Theocharis G and Maroulis I revised the manuscript for important intellectual content; Thomopoulos K and Triantos C offered technical or material support; Triantos C and Diamantopoulou G provided administrative support; all authors have read and approved the final version to be published.

**Institutional review board statement:** The study was reviewed and approved by the Ethics committee of the University Hospital of Patras.

**Informed consent statement:** All study participants, or their legal guardian, provided written or verbal informed consent prior to study enrollment.

**Conflict-of-interest statement:** The Authors have nothing to declare.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at [asraiah@yahoo.com](mailto:asraiah@yahoo.com).

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Christos Konstantakis, MD,** Department of Gastroenterology, General hospital of Patras, 1 Tsertidou St, Patras 26335, Greece. asraiah@yahoo.com

**Telephone**: +30-6974-563157

**Fax**: +30-2613-601893

**Received:** June 29, 2016

**Peer-review started:** July 1, 2016

**First decision:** August 22, 2016

**Revised:** September 17, 2016

**Accepted:** October 17, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To evaluate the rate of recurrence of symptomatic choledocholithiasis and identify factors associated with the recurrence of bile duct stones in patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST) for bile duct stone disease.

***METHODS***

All patients who underwent ERCP and EST for bile duct stone disease and had their bile duct cleared from 1/1/2005 until 31/12/2008 was enrolled. All symptomatic recurrences during the study period (until 31/12/2015) were recorded. Clinical and laboratory data potentially associated with common bile duct (CBD) stone recurrence were retrospectively retrieved from patients’ files.

***RESULTS***

A total of 495 patients were included. Sixty seven (67) out of 495 patients (13.5%) presented with recurrent symptomatic choledocholithiasis after 35.28 ± 16.9 mo while twenty two (22) of these patients (32.8%) experienced a second recurrence after 35.19 ± 23.2 mo. Factors associated with recurrence were size (diameter) of the largest CBD stone found at first presentation (10.2 ± 6.9 mm *vs* 7.2 ± 4.1 mm, *P* = 0.024), diameter of the CBD at the first examination (15.5 ± 6.3 mm *vs* 12.0 ± 4.6 mm, *P* = 0.005), use of mechanical lithotripsy (ML) (*P* = 0.04) and presence of difficult lithiasis (*P* = 0.04). Periampullary diverticula showed a trend towards significance (*P* = 0.066). On the contrary, number of stones, angulation of the CBD, number of ERCP sessions required to clear the CBD at first presentation, more than one ERCP session needed to clear the bile duct initially and a gallbladder in situ did not influence recurrence.

***CONCLUSION***

Bile duct stone recurrence is a possible late complication following endoscopic stone extraction and CBD clearance. It appears to be associated with anatomical parameters (CBD diameter) and stone characteristics (stone size, use of ML, difficult lithiasis) at first presentation.

**Key words:** Bile duct stone disease; Common bile duct angulation; Choledocholithiasis; Endoscopic retrograde cholangiopancreatography; Endoscopic sphincterotomy; Recurrence of choledocholithiasis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Recurrence of choledocholithiasis is considered a late complication following endoscopic extraction of bile duct stones. There are various factors associated with the risk of recurrence. In our study the rate of recurrence was 13.5%. Although univariate analysis identified four different risk factors associated with both anatomical parameters (common bile duct diameter) and stone characteristics (stone size, use of mechanical lithotripsy, difficult lithiasis), multivariate analysis confirmed only bile duct diameter as being important. The underlying pathogenetic mechanism of recurrence is likely multifactorial in nature. Bile stasis, duodenal – biliary reflux and unfavorable stone characteristics probably contribute towards stone reformation.

Konstantakis C, Triantos C, Theopistos V, Theoxaris G, Maroulis I, Diamantopoulou G, Thomopoulos K Recurrence of choledocholithiasis following endoscopic bile duct clearance: long term results and factors associated with recurrent bile duct stones. *World J Gastrointest Endosc* 2016; In press

**INTRODUCTION**

Endoscopic retrograde cholangiopancreatography (ERCP) is widely accepted as the modality of choice for the endoscopic removal of bile duct stones. Endoscopic sphincterotomy (EST) since its introduction in 1974[[1](#_ENREF_1),[2](#_ENREF_2)], has been extensively used for the endoscopic extraction of bile duct stones. Endoscopic techniques for stone removal are generally considered both safe and effective but, their invasive nature cannot preclude the possibility of complications. In fact complications can occur even in the hands of the most seasoned expert[[3](#_ENREF_3)]. They can be broadly classified, depending on their timing, as early (up to 3 d post-procedure) or late (> 3 d)[[4](#_ENREF_4)]. Early complications are mostly related with sedation and endoscopy like bleeding, infection, pancreatitis, perforation, cardiopulmonary events, while late complications concern mainly stent infections due to long-term/permanent stent deployment and post-procedural duct/sphincter of Oddi (SO) inflammatory changes (*i.e.,* ampullary stenosis) because of ductal/SO manipulation[[4](#_ENREF_4)]. Although not officially listed as a late complication of ERCP in various guidelines[[3](#_ENREF_3)], recurrence of choledocholithiasis is considered to be one by many authors[[5-7](#_ENREF_5)]. Rates of recurrence vary across different studies, ranging from 4% to 24% (variable intervals of follow-up of up to 15 years)[[8-10](#_ENREF_8)]. The goal of this paper is to evaluate the rate of recurrence of symptomatic choledocholithiasis and identify factors associated with the recurrence of bile duct stones in patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST) for bile duct stone disease.

**MATERIALS AND METHODS**

***Patients***

We retrospectively studied a group of patients who underwent ERCP and EST for bile duct stone disease at a tertiary center, Department of Gastroenterology of the University hospital of Patras from 1/1/2005 until 31/12/2008. Only patients in whom complete and successful clearance of the common bile duct (CBD) from stones was achieved were included in the study irrespectively of the number of sessions required to fulfill that requirement. Patients with difficult bile duct stones (large bile duct stones (> 10 mm) and / or multiple stones (≥ 3) or impacted stones)[[11](#_ENREF_11)] or residual choledocholithiasis were included in the study as long as a patent CBD was achieved in their baseline or any of their subsequent follow – up examinations. Patients with known residual CBD stones (unable to be extracted or referred for surgical treatment), pancreatic/biliary malignant disorders and benign biliary strictures (usually post – surgery) were excluded from the study, finally patients with indwelling biliary stents (permanent or long standing) and patients that were lost to follow – up were also excluded. Every patient with gallbladder stones was instructed to remove his/her gallbladder surgically after the first (baseline) clearance of the bile duct (if a cholocystectomy was not already performed). All patients were followed up until either termination of the study (31/12/2015) or when they died.

For the purpose of studying recurrence associated risk factors we created two (2) groups. In the first group all patients with a history of symptomatic recurrence were enrolled (after applying exclusion criteria). An equal number (1: 1) of age / gender – matched control patients was selected from the pool of recurrent free patients (group two).

***Endoscopic treatment***

Written informed consent for the ERCP was obtained from all the patients undergoing the procedure. Preparation included local anesthesia of the pharynx using 10% xylocaine, and conscious sedation of the patient with the use of (IV) midazolam – pethidine. Reversal agents (flumazenil) were used when indicated. Antibiotic prophylaxis was used in accordance with published guidelines at the time, the exact regimen depending on the appropriate clinical indication[[12](#_ENREF_12)]. ERCP was performed using a side-view endoscope (Olympus Optical Corporation, Tokyo, Japan). In patients with native papilla EST was performed, after deep canullation of the CBD with the help of a guidewire, using a standard pull-type papillotome according to the standard technique. Before performing the EST a cholangiogram (using a diluted contrast medium) was attainted to confirm CBD stones. Under fluoroscopic/endoscopic guidance stones were removed from the CBD, mainly with the use of ballon catheters and occasionally with dormia retrieval baskets. Patients with difficult stones were treated with either mechanical lithotripsy at the same session or use of temporary plastic stents. Patency of the CBD/clearance of stones was evaluated by absence of any filling defects at the final cholangiogram. During the enrollment period (2005 – 2008) large balloon dilation was not a common practice. As such it was not exercised by our unit.

***Study of the cholangiograms***

Size and number of CBD stones were assessed on the cholangiogram after optimum opacification of the CBD. Stone size was assessed by comparing the diameter of the stone to the (relevant size of the) shaft of the endoscope on the cholangiogram. CBD diameter was measured in a similar manner. Likewise CBD angulation(s) were also calculated from postoperative cholangiograms. All calculations were independently validated by a second observer and any interobserver differences were expressed as mean values.

***Data collection and definitions***

All data was extracted from the first (baseline) ERCP of all patients.

The following parameters were recorded and investigated for the purpose of studying risk factors. (1) Basic demographics : sex and age; (2) Diameter of the CBD (mm); (3) Stone characteristics : size (mm) (defined as the diameter of the largest stone), number of stones, difficult CBD lithiasis (defined as presence of large bile duct stone (> 10 mm) and / or multiple stones (≥ 3) and /or impacted stones [[11](#_ENREF_11)]); (4) Angulation of the CBD : two (2) different angulation scores were assessed (Figure 1)[[13](#_ENREF_13),[14](#_ENREF_14)]; (5) Juxtapapillary duodenal diverticula; (6) Timing of recurrences (early *vs* late); (7) Use of mechanical lithotripsy (ML)

Number of ERCP session required to clear the Bile Duct; and (8) Past medical history: surgical (mainly hepatobililiary/pancreatic): (1) Biliary – enteric anastomosis (BEA); (2) Altered stomach anatomy (gastrectomy or other); and (3) Cholocystectomy/remaining gallbladder (gallbladder that was not surgically removed, termed gallbladder in situ) / gallbladder stones (chololithiasis).

Stone recurrence, for the purpose of this study, was defined by the confirmation of the presence of a CBD stone in the appropriate clinical context at least 6 months after previous (complete) CBD stone removal by ERCP was achieved. Thus we evaluated only clinically significant recurrences (patients exhibiting relevant hepatobiliary symptoms like pain and jaundice).

Multiple recurrences were defined as 2 or more stone recurrences after the first ERCP. In this study early recurrence was defined as a recurrence that occurred up to (and including) 24 mo after the baseline ERCP that CBD patency was achieved (this term applies only to first recurrence episodes). A recurrence after the first 24 mo was termed a late one.

***Follow up***

Clinical and laboratory data potentially associated with common bile duct (CBD) stone recurrence were retrospectively retrieved from patients’ files. Our department belongs in a tertiary hospital. Our hepatobiliary unit acts as regional referral center. The likelihood of patients being referred to another unit would be truly improbable.

***Statistical analysis***

Clinical and ERCP related factors that might have contributed to the recurrence of common bile duct stones were evaluated. All these parameters were correlated with recurrence, initially by using univariate analysis. Continuous variables were expressed as mean ± SD and were compared by using Student's t-test. Categorical variables were expressed as percentages and differences between groups were tested for significance by using the χ2 test. Variables found to be significant in the univariate analysis (P-value less than 0.05) were included in a multivariate stepwise logistic regression model. All analyses were conducted by using statistical software SPSS, version 20 (SPSS, Inc, Chicago, IL, United State).

**RESULTS**

Between January 2005 and (including) December 2008, 511 unique patients were treated in our center for choledocholithiasis / microcholedocholithiasis (Figure 2). All symptomatic recurrences for the study period (until December 2015) were recorded, after applying exclusion criteria. 16 patients that were lost to follow – up were dropped from the study. Sixtyseven (67) out of 495 patients (13.5%) presented with recurrent symptomatic choledocholithiasis after 35.28 ± 16.909 (7-96) mo while twenty two (22) of these patients (32.83% of the recurrent) experienced a second recurrence after 35.19 ± 23.22 (9-78) mo. A 3rd recurrence occurred to 6 (8.9%) of the recurrent patients at 16.83 ± 15.3 mo (Table 1).

The number of procedures/ ERCPs required to treat the recurrent population (baseline ERCP, recurrence examinations including any follow – up procedures that were required to achieve CDB patency) is summarized in Table 2. An impressive total of 199 ERPCs was required to treat the 67 recurrent patients over time. On the other hand for the 67 controls a total of 89 ERCP sessions was needed.

Early recurrences (recurrence during the first 24 mo after the baseline ERCP) occurred in 21/67 patients (46/67 late).

Multiple recurrences occurred in 22 patients (Table 1). We have found that an early recurrence predisposes to multiple recurrences more often than a late one. Thirteen (13) out of the 21 early recurrent patients (13/21) had a second recurrence, while only 14/46 of those with late recurrence suffered from a second episode (*P* = 0.0025).

For the purpose of studying risk factors, the 67 patients with a history of symptomatic recurrence were compared to a group of 67 age / gender – matched control patients that were selected from a pool of 428 patients with a recurrent free history. Baseline characteristics for both groups are presented in Table 3.

No significant differences were found with regard to age, sex, previous surgical history (including cholecystectomy before the baseline (first) ERCP and biliary, gastric surgery) and mean follow –up time between the groups.

Table 4 summarizes the risk factors for recurrence that were evaluated.

Logistic regression analyses were performed to identify the risk factors for stone recurrence, including both baseline characteristics and ERCP-related parameters. Univariate analysis revealed that diameter of the CBD, size (diameter) of the largest CBD stone, use of ML and difficult lithiasis were associated with stone recurrence. Multivariate analysis revealed that CBD diameter was the only independent risk factor associated with CBD stone recurrence (OR = 1.116, 95% CI: 1.005 – 1.277, *P* = 002).

**DISCUSSION**

The recurrence of CBD stones is a possible outcome following endoscopic clearance[[5](#_ENREF_5),[6](#_ENREF_6)]. Rates of recurrence in the literature vary with some authors estimating them being as high as 24%[[8-10](#_ENREF_8)]. So although it is considered a late complication of stone extraction, it certainly is not a rare one. Many authors report that most recurrences of bile duct stones take place in the first 3 years[[15](#_ENREF_15),[16](#_ENREF_16)], the limit between recurrence and residual stone disease is somewhat arbitrary with many authors advocating for the threshold of 5[[16](#_ENREF_16)] to 6[[15](#_ENREF_15)] mo.

Bile duct stones (and as a result also recurrent stones) are classified as primary or secondary stones, both with different pathogenesis and etiologies[[17](#_ENREF_17)]. A stone is termed primary when located at the site of its formation, while a secondary stone is a stone that has migrated from the site of its origin (in this case usually the gallbladder). Thus, primary CBD stones form de novo in the CBD, these are usually brown pigment (calcium bilirubinate) stones, where they remain either uneventfully or until they are implicated in a clinical sequela (*e.g.,* cholangitis )[[18](#_ENREF_18)]. Secondary CBD stones are commonly associated with migrating gallbladder (or rarely intrahepatic) stones and thus consist mainly of cholesterol.

There’s a plethora of risk factors related with recurrence of choledocholithiasis proposed in the literature; many of these are summarized in Table 5.

The putative mechanism responsible for stone recurrences still eludes us. In some cases, like secondary CBD stones in patients with concurrent chololithiasis, the underlying cause is in most probability also the most obvious one (*i.e.,* stone migration from the stone-ridden gallbladder to the CBD). After reviewing the literature it is obvious that there is no consensus reached in the scientific community on the exact mechanism. We could argue that at the present there are two dominating theories.

***Endobiliary Bile Stasis (endo – Bi.S.)***[[18](#_ENREF_18),[19](#_ENREF_19),[22](#_ENREF_22),[31](#_ENREF_31)]

The term endobiliary bile stasis encloses a variety of risk factors that predispose to biliary stasis, delayed biliary emptying and/or impaired biliary flow. Acute distal CBD angulation, oblique CBD angulation, CBD dilation, periampullary diverticula, billiary strictures, papillary stenosis, cirrhosis, cholocystectomy, possibly genetic factors (like variations of the ABCB4, ABCB11 genes) have been associated with biliary stasis and the formation of primary CBD stones and their recurrence. Mechanical obstruction/blockage as well as variations in the (patho)physiology of bile secretion ( bile viscosity, bile secretion rate, loss of bile flushing due to cholocystectomy ) could help to explain why a bile duct system exhibiting any number of these anatomic/physiology abnormalities could be predisposed to stone recurrence.

***Duodenal - biliary reflux***[[6](#_ENREF_6),[19-23](#_ENREF_19),[27](#_ENREF_27)]

This term encompasses a number of factors that are associated with the reflux of enteric contents (fluid and/or solid chime) inside the biliary tract. Pneumobilia[[19](#_ENREF_19)], post-procedural impaired sphincter function (EST / EPLBD ), bacterial infection/colonization of the CBD, EST size are all factors that have been related to duodenal reflux. Recent studies have drawn our focus towards the role that post - procedural sphincter functional adequacy has in Duodenal – Biliary Reflux (DBR) in particular and in stone recurrence in general. It has been suggested that sphincter preserving procedures (small size EST, EPSBD) exert a protective role, reducing the risk of recurrence. Permanent sphincter function disruption by EST or EPLBD could result in duodenobiliary reflux.

The underlying pathogenesis of stone recurrence is not yet fully elucidated. To a great extent clinical practice has proceeded basic research[[32](#_ENREF_32)]. A multifactorial model where chronic inflammation of the bile ducts plays a central role could help to better explain it. Bile stagnation, reflux of duodenal content, bacterial colonization and chronic infection of the CBD as well as mechanical and chemical damaging effects of chronic irritants (from the enteric content) could all contribute to sustain chronic inflammation.[[25](#_ENREF_25),[26](#_ENREF_26)].

In our study we found that CBD dilation, stone size at first presentation, difficult lithiasis and use of mechanical lithotripsy were all risk factors for stone recurrence in the univarate analysis. These findings are similar to those of previous reports[[6](#_ENREF_6),[19](#_ENREF_19),[22](#_ENREF_22),[24](#_ENREF_24),[31](#_ENREF_31)] . We could argue that large stone size, presence of difficult lithiasis and need for mechanical lithotripsy is all different aspects of the same factor. In a way they serve to prove that patients with certain ‘’ unfavorable stone characteristics’’ recur more often than others. Multivariate analysis revealed that the diameter of the common bile duct was the only independent risk factor associated with stone recurrence. It has been suggested before that CBD dilation above a certain threshold (13 mm)[[21](#_ENREF_21)] and especially excessive dilation (> 20 mm) [[31](#_ENREF_31)] predispose to stone reformation. In our study, the issue of a cut-off value of CBD diameter that predisposes to higher rates of recurrence was addressed but we did not reach a statistically significant result (probably due to the sample size). Periampullary diverticula showed a trend towards significance in our study (*P* = 0.066), unlike the clear association reported by other authors[[19](#_ENREF_19),[29](#_ENREF_29)]. This is probably so because of the small sample in our study.

It has been proposed that patients with recurring CBD stones are at increased risk for a subsequent recurrence[[7](#_ENREF_7)]. Data from our study is also in support. Patients who suffered from a recurrence were in a much greater danger. Thirty-two percent of the recurrent population had at least a second episode, while the recurrence rate for a patient who has not experienced a recurrence before was 13.5%. Data from the aforementioned study[[7](#_ENREF_7)] identified an interval of ≤ 5 years between initial EST and repeat ERCP as a risk factor for re – recurrence. Likewise, patients from our cohort who suffered from an early (≤ 24 mo) recurrence attack, were at increased risk for consequent episodes.

There are several limitations in this study including its retrospective design, single-center site and the relative small sample size. We acknowledge that because of both the retrospective design and the often asymptomatic nature of CBD stones, several methodological issues concerning mainly the follow-up of patients and data collection could arise. A prospective multi center cohort study needs to be conducted to investigate further the association between these risks factors and stone recurrence. This study needs to be powered by both a large sample size and a long follow-up (longer than five years)[[29](#_ENREF_29)]. Last but not least future studies need to focus more on possible clinical applications. Bedside questions that need to be answered like˙ which patients should we follow-up? Is there any patient group with specific characteristics (*e.g.,* CBD dilation above a certain threshold) that justify more intensive follow-up? What is the importance of asymptomatic stones in multi-recurring patients, can these patients benefit from pre-emptive/prophylactic ERCP, what’s the hazard/benefit ratio?

In conclusion, bile duct stone recurrence is a likely late complication following endoscopic stone extraction and CBD clearance. In our study the rate of recurrent symptomatic choledocholithiasis was 13.5%. It appears to be associated with both anatomical parameters (CBD diameter) and stone characteristics (stone size, use of ML, difficult lithiasis) at first presentation.

**COMMENTS**

***Background***

Endoscopic retrograde cholangiopancreatography (ERCP) is widely accepted as the modality of choice for the endoscopic removal of bile duct stones. Endoscopic sphincterotomy (EST) since its introduction in 1974, has been extensively used for the endoscopic extraction of bile duct stones. Endoscopic techniques for stone removal are generally considered both safe and effective but, their invasive nature cannot preclude the possibility of complications.

***Research frontiers***

Many authors report that most recurrences of bile duct stones take place in the first 3 years the limit between recurrence and residual stone disease is somewhat arbitrary with many authors advocating for the threshold of 5 to 6 mo.

***Innovations and breakthroughs***

In this study, the issue of a cut-off value of CBD diameter that predisposes to higher rates of recurrence was addressed but the authors did not reach a statistically significant result (probably due to the sample size). Periampullary diverticula showed a trend towards significance in our study (*P* = 0.066), unlike the clear association reported by other authors.

***Peer-review***

This manuscript is very well designed, the authors did a great effort in selecting the articles to be included in the meta-analysis with a proper quality scoring of selected articles. I think this manuscript is suitable for publication.

**REFERENCES**

1 **Classen M**, Demling L. [Endoscopic sphincterotomy of the papilla of vater and extraction of stones from the choledochal duct (author's transl)]. *Dtsch Med Wochenschr* 1974; **99**: 496-497 [PMID: 4835515 DOI: 10.1055/s-0028-1107790]

2 **Kawai K**, Akasaka Y, Murakami K, Tada M, Koli Y. Endoscopic sphincterotomy of the ampulla of Vater. *Gastrointest Endosc* 1974; **20**: 148-151 [PMID: 4825160]

3 **Anderson MA**, Fisher L, Jain R, Evans JA, Appalaneni V, Ben-Menachem T, Cash BD, Decker GA, Early DS, Fanelli RD, Fisher DA, Fukami N, Hwang JH, Ikenberry SO, Jue TL, Khan KM, Krinsky ML, Malpas PM, Maple JT, Sharaf RN, Shergill AK, Dominitz JA. Complications of ERCP. *Gastrointest Endosc* 2012; **75**: 467-473 [PMID: 22341094 DOI: 10.1016/j.gie.2011.07.010]

4 **Silviera ML**, Seamon MJ, Porshinsky B, Prosciak MP, Doraiswamy VA, Wang CF, Lorenzo M, Truitt M, Biboa J, Jarvis AM, Narula VK, Steinberg SM, Stawicki SP. Complications related to endoscopic retrograde cholangiopancreatography: a comprehensive clinical review. *J Gastrointestin Liver Dis* 2009; **18**: 73-82 [PMID: 19337638]

5 **Cheon YK**, Lehman GA. Identification of risk factors for stone recurrence after endoscopic treatment of bile duct stones. *Eur J Gastroenterol Hepatol* 2006; **18**: 461-464 [PMID: 16607138]

6 **Kim KY**, Han J, Kim HG, Kim BS, Jung JT, Kwon JG, Kim EY, Lee CH. Late Complications and Stone Recurrence Rates after Bile Duct Stone Removal by Endoscopic Sphincterotomy and Large Balloon Dilation are Similar to Those after Endoscopic Sphincterotomy Alone. *Clin Endosc* 2013; **46**: 637-642 [PMID: 24340257 DOI: 10.5946/ce.2013.46.6.637]

7 **Sugiyama M**, Suzuki Y, Abe N, Masaki T, Mori T, Atomi Y. Endoscopic retreatment of recurrent choledocholithiasis after sphincterotomy. *Gut* 2004; **53**: 1856-1859 [PMID: 15542528 DOI: 10.1136/gut.2004.041020]

8 **Freeman ML**, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. *N Engl J Med* 1996; **335**: 909-918 [PMID: 8782497 DOI: 10.1056/nejm199609263351301]

9 **Prat F**, Malak NA, Pelletier G, Buffet C, Fritsch J, Choury AD, Altman C, Liguory C, Etienne JP. Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis. *Gastroenterology* 1996; **110**: 894-899 [PMID: 8608900]

10 **Hawes RH**, Cotton PB, Vallon AG. Follow-up 6 to 11 years after duodenoscopic sphincterotomy for stones in patients with prior cholecystectomy. *Gastroenterology* 1990; **98**: 1008-1012 [PMID: 2311858]

11 **Ding J**, Li F, Zhu HY, Zhang XW. Endoscopic treatment of difficult extrahepatic bile duct stones, EPBD or EST: An anatomic view. *World J Gastrointest Endosc* 2015; **7**: 274-277 [PMID: 25789099 DOI: 10.4253/wjge.v7.i3.274]

12 **Khashab MA**, Chithadi KV, Acosta RD, Bruining DH, Chandrasekhara V, Eloubeidi MA, Fanelli RD, Faulx AL, Fonkalsrud L, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Shaukat A, Wang A, Cash BD. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc* 2015; **81**: 81-89 [PMID: 25442089 DOI: 10.1016/j.gie.2014.08.008]

13 **Seo DB**, Bang BW, Jeong S, Lee DH, Park SG, Jeon YS, Lee JI, Lee JW. Does the bile duct angulation affect recurrence of choledocholithiasis? *World J Gastroenterol* 2011; **17**: 4118-4123 [PMID: 22039327 DOI: 10.3748/wjg.v17.i36.4118]

14 **Keizman D**, Shalom MI, Konikoff FM. An angulated common bile duct predisposes to recurrent symptomatic bile duct stones after endoscopic stone extraction. *Surg Endosc* 2006; **20**: 1594-1599 [PMID: 16858527 DOI: 10.1007/s00464-005-0656-x]

15 **Tanaka M**, Takahata S, Konomi H, Matsunaga H, Yokohata K, Takeda T, Utsunomiya N, Ikeda S. Long-term consequence of endoscopic sphincterotomy for bile duct stones. *Gastrointest Endosc* 1998; **48**: 465-469 [PMID: 9831833]

16 **Lai KH**, Lo GH, Lin CK, Hsu PI, Chan HH, Cheng JS, Wang EM. Do patients with recurrent choledocholithiasis after endoscopic sphincterotomy benefit from regular follow-up? *Gastrointest Endosc* 2002; **55**: 523-526 [PMID: 11923765]

17 **Kim DI**, Kim MH, Lee SK, Seo DW, Choi WB, Lee SS, Park HJ, Joo YH, Yoo KS, Kim HJ, Min YI. Risk factors for recurrence of primary bile duct stones after endoscopic biliary sphincterotomy. *Gastrointest Endosc* 2001; **54**: 42-48 [PMID: 11427840]

18 **Saharia PC**, Zuidema GD, Cameron JL. Primary common duct stones. *Ann Surg* 1977; **185**: 598-604 [PMID: 857748]

19 **Zhang R**, Luo H, Pan Y, Zhao L, Dong J, Liu Z, Wang X, Tao Q, Lu G, Guo X. Rate of duodenal-biliary reflux increases in patients with recurrent common bile duct stones: evidence from barium meal examination. *Gastrointest Endosc* 2015; **82**: 660-665 [PMID: 25952091 DOI: 10.1016/j.gie.2015.03.1908]

20 **Ando T**, Tsuyuguchi T, Okugawa T, Saito M, Ishihara T, Yamaguchi T, Saisho H. Risk factors for recurrent bile duct stones after endoscopic papillotomy. *Gut* 2003; **52**: 116-121 [PMID: 12477771]

21 **Baek YH**, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. [Risk factors for recurrent bile duct stones after endoscopic clearance of common bile duct stones]. *Korean J Gastroenterol* 2009; **54**: 36-41 [PMID: 19696548]

22 **Tsai TJ**, Lai KH, Lin CK, Chan HH, Wang EM, Tsai WL, Cheng JS, Yu HC, Chen WC, Hsu PI. Role of endoscopic papillary balloon dilation in patients with recurrent bile duct stones after endoscopic sphincterotomy. *J Chin Med Assoc* 2015; **78**: 56-61 [PMID: 25241239 DOI: 10.1016/j.jcma.2014.08.004]

23 **Itokawa F**, Itoi T, Sofuni A, Kurihara T, Tsuchiya T, Ishii K, Tsuji S, Ikeuchi N, Umeda J, Tanaka R, Tonozuka R, Honjyo M, Moriyasu F, Kasuya K, Tsuchida A. Mid-term outcome of endoscopic sphincterotomy combined with large balloon dilation. *J Gastroenterol Hepatol* 2015; **30**: 223-229 [PMID: 24995677 DOI: 10.1111/jgh.12675]

24 **Mu H**, Gao J, Kong Q, Jiang K, Wang C, Wang A, Zeng X, Li Y. Prognostic Factors and Postoperative Recurrence of Calculus Following Small-Incision Sphincterotomy with Papillary Balloon Dilation for the Treatment of Intractable Choledocholithiasis: A 72-Month Follow-Up Study. *Dig Dis Sci* 2015; **60**: 2144-2149 [PMID: 25875753 DOI: 10.1007/s10620-015-3559-2]

25 **Ishiguro J**. Biliary bacteria as an indicator of the risk of recurrence of choledocholithiasis after endoscopic sphincterotomy. *Diagn Ther Endosc* 1998; **5**: 9-17 [PMID: 18493475 DOI: 10.1155/dte.5.9]

26 **Kim KH**, Rhu JH, Kim TN. Recurrence of bile duct stones after endoscopic papillary large balloon dilation combined with limited sphincterotomy: long-term follow-up study. *Gut Liver* 2012; **6**: 107-112 [PMID: 22375179 DOI: 10.5009/gnl.2012.6.1.107]

27 **Lai KH**, Chan HH, Tsai TJ, Cheng JS, Hsu PI. Reappraisal of endoscopic papillary balloon dilation for the management of common bile duct stones. *World J Gastrointest Endosc* 2015; **7**: 77-86 [PMID: 25685263 DOI: 10.4253/wjge.v7.i2.77]

28 **Lu Y**, Wu JC, Liu L, Bie LK, Gong B. Short-term and long-term outcomes after endoscopic sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones. *Eur J Gastroenterol Hepatol* 2014; **26**: 1367-1373 [PMID: 25264985 DOI: 10.1097/meg.0000000000000218]


29 **Chang JH**, Kim TH, Kim CW, Lee IS, Han SW. Size of recurrent symptomatic common bile duct stones and factors related to recurrence. *Turk J Gastroenterol* 2014; **25**: 518-523 [PMID: 25417612 DOI: 10.5152/tjg.2014.6457]

30 **Pan S**, Li X, Jiang P, Jiang Y, Shuai L, He Y, Li Z. Variations of ABCB4 and ABCB11 genes are associated with primary intrahepatic stones. *Mol Med Rep* 2015; **11**: 434-446 [PMID: 25323205 DOI: 10.3892/mmr.2014.2645]


31 **Paik WH**, Ryu JK, Park JM, Song BJ, Kim J, Park JK, Kim YT. Which is the better treatment for the removal of large biliary stones? Endoscopic papillary large balloon dilation versus endoscopic sphincterotomy. *Gut Liver* 2014; **8**: 438-444 [PMID: 25071911 DOI: 10.5009/gnl.2014.8.4.438]

32 **Hisatomi K**, Ohno A, Tabei K, Kubota K, Matsuhashi N. Effects of large-balloon dilation on the major duodenal papilla and the lower bile duct: histological evaluation by using an ex vivo adult porcine model. *Gastrointest Endosc* 2010; **72**: 366-372 [PMID: 20674625 DOI: 10.1016/j.gie.2010.02.002]

**P-Reviewer:** Lai KH, Pan H **S-Editor:** Qi Y **L-Editor: E-Editor:**



**Figure 1 Common bile duct angulation calculation methods.** Accumulative score (pictures A and B): The axis (red line) runs through the center of the CBD. Each internal angle was measured at the angulation of the proximal (A) and distal (B) bile duct level respectively. The values of both angles were added (A + B). If either part of the CBD was not angulated a set score of 180 was used[13]. Minimal angle score (picture C): Angulation (A) was measured as the sharpest angle along the CBD from 1 cm below the bifurcation to 1 cm above the papilla[14].



**Figure 2 Study flowchart.**

**Table 1 Number and percentage of patients who experienced one or more (up to five) symptomatic recurrences**

|  |  |
| --- | --- |
| Ref. | Patients (*n* = 67) *n* (%) |
| 1 | 45 (67.1) |
| 2 | 16 (23.8) |
| 3 | 4 (5.9) |
| 4 | 1 (1.5) |
| 5 | 1 (1.5) |

Most of the patients experienced only a single episode (67%).

**Table 2 Number and percentage of endoscopic retrograde cholangiopancreatography required to treat patients with recurrence**

|  |  |
| --- | --- |
| Number of ERCP sessions | Patients (*n* = 67) *n* (%) |
| 2 | 31 (46) |
| 3 | 16 (23.8) |
| 4 | 13 (19) |
| 5 | 5 (7.46) |
| 6 | 2 (2.98) |

ERCP: Endoscopic retrograde cholangiopancreatography.

**Table 3 Baseline characteristics of the study groups**

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | Recurrence group  (*n* = 67) | Control  group  (*n* = 67) | *P* value |
| Age, yr | 71.2 ± 12.4 | 71.9 ± 12.6 | 0.82 |
| Sex, male | 26/67 | 28/67 | 0.86 |
| History of cholecystectomy  before first ERCP | 37 | 40 | 0.73 |
| BEA /gastric surgery | 4  (2 billroth, 2 BEA) | 2  (1 billroth, 1 BEA) | 0.68 |
| Mean follow – up time, months | 70,1 ± 31.7  (2-121) | 68.5 ± 36.1  (1-129) | 0.80 |

# Recurrence group: Patients with a history of recurrent common bile duct stones; Control group: Patients with a history of non recurrent common bile duct stones; BEA: Biliary enteric anastomosis.

**Table 4 Parameters of the first ERCP/risk factors for recurrence in patients with or without a history of recurrent common bile duct stones**

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | Recurrence group  (*n* = 67) | Control group  (*n* = 67) | *P* value |
| Stone size, mm | 11.0 ± 7.0 | 7.5 ± 4.5 | 0.007 |
| Stone number, n | 4.9 ±4.4 | 4.3 ± 4.7 | 0.53 |
| CBD diameter, mm | 16.03 ± 6.1 | 12.0 ± 4.6 | 0.001 |
| CBD angulation method 1 (accumulative score) | 303.97 ± 34.41 | 304.84 ± 31.61 | 0.91 |
| CBD angulation method 2 (minimal angle score) | 137.03 ± 17.0 | 138.41 ± 14.18 | 0.71 |
| Difficult bile duct stones | 24 | 14 | 0.04 |
| Use of mechanical lithotripsy | 13 | 5 | 0.04 |
| Number of ERCP sessions required to clear the Bile Duct | 1.33 ± 0.6 | 1.34 ± 0.7 | 0.95 |
| More than one ERCP needed to clear the bile duct initially | 14 | 11 | 0.43 |
| Gallbladder in situ | 2 | 5 | 1.0 |
| Periampullary diverticula | 25 | 16 | 0.066 |

Gallbladder in situ (remaining gallbladder): patients who did not/could not conform to the instructions to perform cholocystectomy after the first ERCP, or a cholocystectomy was not indicated.

**Table 5 Risk factors for recurrence of choledocholithiasis proposed in the literature**

|  |  |  |
| --- | --- | --- |
| Proposed risk factor | Ref | Comment section |
| DBR | [[19-21](#_ENREF_19)] | DBR |
| Pneumobilia | [[19](#_ENREF_19)] | Indicative of DBR |
| Acute distal CBD angulation | [[19](#_ENREF_19)] | Promotes bile stasis |
| CBD dilation | [[19](#_ENREF_19)] | Promotes bile stasis |
| Periampullary diverticulum | [[19](#_ENREF_19)] | Promotes bile stasis |
| Prior EST | [[22](#_ENREF_22), [23](#_ENREF_23)] | Promotes DBR |
| Intact gallbladder with stones in situ | [[22](#_ENREF_22)] | (Secondary) stone CBD migration |
| Billiary stricture | [[22](#_ENREF_22)] | Promotes bile stasis |
| Papillary stenosis | [[22](#_ENREF_22)] | Promotes bile stasis |
| ML | [[22](#_ENREF_22)] | Small residual microlithiasis acts as nidi for stone formation |
| Stone size | [[24](#_ENREF_24)] | Size of the largest stone |
| Cirrhosis | [[22](#_ENREF_22)] | Delayed biliary emptying / bile stasis |
| Delayed biliary emptying | [[22](#_ENREF_22)] | Promotes bile stasis |
| Bacterial infection/colonization of the CBD. Bacterial count. | [[25](#_ENREF_25), [26](#_ENREF_26)] | Promotes chronic infection, and inflammation, promotes stone formating |
| Impaired biliary flow | [[25](#_ENREF_25)] | Scintigraphic study |
| Cholecystectomy (without stones) | [[27](#_ENREF_27)] | Impede flushing of nidus/residual stones |
| Post-procedural sphincter function impaired | [[6](#_ENREF_6), [27](#_ENREF_27)] | EST *vs* EPBD / EPLBD *vs* EPSBD, promote DBR |
| Number of sessions to clear duct at first presentation | [[6](#_ENREF_6)] | # of ERCPs required to achieve a patent CBD |
| Age | [[6](#_ENREF_6)] | Old age |
| Previous cholecystectomy (open or lap) | [[6](#_ENREF_6)] |  |
| Serum lvls of chol. | [[24](#_ENREF_24)] | Lithogenic properties |
| EST size | [[24](#_ENREF_24)] | Minimal size is protective |
| Inflammation CBD | [[24](#_ENREF_24)] |  |
| Parasites of the CBD | [[24](#_ENREF_24)] | Parasitic infenction |
| Foreign bodies in the CBD | [[24](#_ENREF_24)] |  |
| Concurrent cholecystolithiasis and cholelithiasis | [[28](#_ENREF_28)] |  |
| Post stone removal CBD diameter | [[21](#_ENREF_21)] | At 72 h after stones removal, cholangiogram via nasobiliary tube |
| EPLBD > 10mm | [[29](#_ENREF_29)] | Disruption of SO, DBR |
| Variations of the ABCB4, ABCB11 genes | [[30](#_ENREF_30)] | Affect composition of bile. Associated with cholestasis, cholelithiasis and formation of primary intrahepatic stones |
| Excessive dilation of the CBD | [[31](#_ENREF_31)] | Recurrence rate was 40% when maximum CBD diameter was more than 20 mm, whereas recurrence rate was 18% when maximum CBD diameter was 20 mm or less |

The level of evidence varies. DBR: Duodenal-biliary reflux; CBD: Common bile duct; EST: Endoscopic sphincterotomy; ML: Mechanical lithotripsy; EPBD: Endoscopic papillary balloon dilation; EPLBD: Endoscopic papillary large balloon dilation; EPSBD: Endoscopic papillary small balloon dilation; ERCP: Endoscopic retrograde cholangiopancreatography; Llv: Level; Chol: Cholesterol; SO: Sphincter of Oddi.